Portal de Periódicos da CAPES

Pharmacokinetics of the peritoneal-plasma barrier after systemic mitomycin C administration

1996; Springer Science+Business Media; Linguagem: Inglês

10.1007/978-1-4613-1247-5_3

2509-8497

Paul H. Sugarbaker, O. Anthony Stuart, Joan Vidal-Jové, A Pessagno, E A DeBruijn,

Pancreatic and Hepatic Oncology Research

Intraperitoneal administration of drugs continues to be of considerable interest for regional and systemic drug delivery in both animals and humans. There have been extensive studies, notably by Lukas et al. [1] and Torres et al. [2], to determine the pharmacokinetics involved in the transport of drugs from the peritoneal cavity into the portal and systemic circulation. In recent years, interest in the exchange of substances between the peritoneal cavity and the systemic circulation has been focused on humans. This has been stimulated in large part by the utilization of chronic peritoneal dialysis for patients in renal failure. Also, the peritoneal cavity is an important site for the spread of cancer from gastrointestinal and ovarian tumors. Controversy currently exists regarding the use of intraperitoneal chemotherapy to optimize the management of cancers that involve the peritoneal surfaces. Investigations of the pharmacokinetics involved during the transport of drugs from the peritoneum into the blood gave birth to the pharmacologic entity known as the peritoneal-plasma barrier (PPB) [3–7].